Twenty-two patients under general practice care, suffering mild to moderate hypertension and receiving no active treatment had three baseline blood pressure measurements taken during a single blind 4-week placebo run-in period. One patient wits secondarily excluded at this stage because of a placebo response and one patient dropped out for personal reasons. The remaining 20 patients were randomized to receive either nifedipine 20 mg twice a day or mefruside 25 mg once a day in a classical two-period crossover design with 8-week treatment periods separated by a 4-week single-blind placebo washout. During 8 weeks nifedipine therapy the mean supine blood pressure was reduced from 173 mmHg. Since blood pressures returned to within 4% of baseline values by the end of the placebo washout period it can be inferred that each therapy was a significant (P<0-05 for all blood pressure variables) antihypertensive treatment in its own right.
Introduction
At the present time, step care therapy for hypertensive patients is widely accepted (Bannan, Beevers and Wright, 1981) with the choice for first line therapy being either a thiazide diuretic or a beta-adrenoceptor blocking agent. Thiazide diuretics have been linked with gout, potassium loss and maturity onset diabetes and are not usually selected for long-term therapy unless a beta-blocking agent is contraindicated as for older patients, black patients, those with heart failure, obstructive airways disease or brittle diabetes (Bannan et aL, 1981) .
The calcium antagonist, nifedipine, formulated as a controlled release preparation (Adalat Retard) is effective when administered twice daily (Gould et al., 1982) , and does not have the side effect profile of thiazide diuretics (Maeda et al., 1982) nor the restrictive contra-indications of beta-blocking drugs. Initial headache and facial flushing are the main side effects of nifedipine therapy.
Nifedipine should therefore be considered for first line therapy providing comparable efficacy is demonstrated with established treatments, i.e. thiazide diuretics and beta-blocking drugs.
Mefruside is a thiazide-like diuretic with an unusually potent antihypertensive effect, equivalent (when given 25 mg daily) to atenolol (100-400 mg daily) over a period of 18 months (Sivertsson, Andersson and Hansson, 1979) . Furthermore, it is claimed that potassium and metabolic disturbances are minimal (Henningsen et al., 1980 ) and short-and long-term tolerance good.
As first line antihypertensive therapy is often initiated by the general practitioner, it was appropriate to conduct this study in a general practice setting.
Materials and methods
The study was randomized using a double-blind, double dummy crossover design with 4-week placebo run-in and washout phases and 8-week treatment periods. During the treatment periods patients received either 25 The patients attended every 4 weeks over the subsequent 20 weeks and on each occasion blood pressure was measured together with heart rate and weight.
At each patient attendance the practice nurse recorded the blood pressure using a Hawksley random zero sphygmomanometer after the patient had been lying for 5 min and then on standing. The same procedure was repeated (A.P.D-J.) before comparing the results, which were then averaged. As well as enquiring after coincidental illness and concomitant medication the patient was asked specifically 'Did your treatment upset you?'. A description and rating of evoked adverse effects was then entered onto the record sheets. An assessment of compliance was made on each occasion by counting returned tablets. Serial biochemical measurements were made throughout the study.
For each of the blood pressure variables, internal validation of the crossover design was performed according to the method described by Armitage and Hills (1979) . Standard t-tests were used for hypothesis testing.
Results
The distributions of relevant pre-entry variables are shown in Table 1 . There were no significant differences between those receiving either drug first. The validity of the crossover study was established with respect to the blood pressure variables there being no discernable period or interaction effects (calculations for the supine diastolic measurements are available from the authors). Therefore both treatment periods were combined in reporting the results.
The effects of nifedipine and mefruside on systolic and diastolic blood pressure, both standing and lying are shown in Fig. 1 .
Over an 8-week treatment period under nifedipine therapy, the mean supine blood pressure was reduced from 173(s. drug on heart rate. Weight was unaffected by either drug and did not change with time. There were no significant differences either within or between treatments with respect to the following biochemical variables: serum sodium, serum potassium, serum calcium, serum uric acid, urea and random blood glucose. However, one patient developed hypokalaemia (serum K+ = 2-9 mmol/l) on mefruside. All other patients maintained a serum potassium concentration above 3-5 mmol/l on both therapies.
The evoked patient complaints and recorded side effects are shown in Table 2 . No patient suffered any serious adverse effects and all evoked complaints were recorded as tolerable.
Discussion
Both nifedipine and mefruside are effective antihypertensive therapies in their own rights as evidenced by the respective blood pressure lowering effects with time. This statement is strengthened by the observation that blood pressures returned to within 4% of pre-treatment levels by the end of the placebo washout phase. There was no significant difference between therapies in respect of systolic and diastolic blood pressure variables but the question remained as to their comparability. The crossover technique was validated showing no period or interaction effects before combining the therapeutic responses from both treatment periods. Following this a particular variable of interest, the supine diastolic blood pressure, was analysed and it was determined that the treatments could be considered equivalent within 6.9 mmHg and with a power of 80o.
This claim though modest, was only possible by investing effort initially in reducing observer error, conducting the study in a double-blind fashion, removing subjective error from blood pressure measurements and validating the crossover design afterwards. To establish more equal efficacy between two powerful antihypertensive agents, i.e. to within 5 mmHg with a power of 95%, would require approximately 60 patients. Thus, nifedipine and mefruside are shown to have a reasonably comparable antihypertensive effect.
The biochemical profiles were not significantly affected by either drug during the relatively short treatment periods. This supports the claim that potassium and metabolic disturbances are minimal with mefruside. The evoked side effects were tolerable, none necessitating withdrawal from the study.
In conclusion, nifedipine, taken twice daily as the controlled release formulation, is an effective antihypertensive agent with an efficacy comparable to the potent thiazide-like diuretic, mefruside. To date, nifedipine has not been implicated in long-term metabolic disturbances sometimes associated with thiazide diuretics.
Nifedipine can also be used in circumstances in which beta-blockers are contra-indicated. This study suggests that nifedipine may therefore be considered as a safe and effective first-line therapy of mild to moderate hypertension in the general practice setting. 
